Our Medicines

Help Shape Patient Care

The medicines listed below are available in Canada. You will find Product Monographs and Patient Medication Information (also known as Consumer Information). You will also find instructions for how to use our devices. Documents provided are for informational use and for residents of Canada only.

If you are a consumer and have questions about Lilly medicines, please call our Customer Response Centre at 1-888-545-5972. If you are seeking medical advice, contact your health care provider.

Lilly is committed to patient safety. Our goal is to ensure that the benefits and risks of our medicines are monitored and understood. Click here to learn more.

We are also committed to keeping people informed about the availability of our medicines. In the event of a shortage or discontinuation, we will post an update on Drug Shortages Canada.

Product Product Monograph Patient Medication Information / Consumer Information User Manual / Instructions for Use Additional Information
Adcirca® (tadalafil)    
Alimta® (pemetrexed disodium for injection)    
Axiron® (testosterone topical solution, 2%)


Discontinued in Canada effective December 4th, 2017.

Discontinued in Canada effective December 4th, 2017.

   
Basaglar® (insulin glargine [rDNA origin] injection) Basaglar® KwikPen®    
Cialis® (tadalafil)   Health Care Professional Letter (June 2006)

Public Communication (June 2006)
   
Cymbalta® (duloxetine hydrochloride)   Health Care Professional Letter (January 2008)    
Cyramza® (ramucirumab)    
Effient® (prasugrel hydrochloride)   Health Care Professional Letter (January 2014)

Public Communication (January 2014)
   
Entuzity™ KwikPen® (insulin injection 500 units/mL, human biosynthetic) Entuzity™ KwikPen®    
Erbitux®∗ (cetuximab)    
Evista® (raloxifene hydrochloride)   Health Care Professional Letter (May 2006)

Public Communication (May 2006)
   
Forteo® (teriparatide [rDNA origin] injection) Forteo® 2.4 mL Pen  
Glucagon (glucagon for injection, rDNA origin) Glucagon Handling Instructions - Video  
Glyxambi™+ (empagliflozin and linagliptin tablets)    

Humalog® (insulin lispro for injection)
Humalog® 200 units/mL KwikPen® (insulin lispro for injection)
Humalog® Mix25® (25% insulin lispro injection, 75% insulin lispro protamine suspension)
Humalog® Mix50® (50% insulin lispro injection, insulin lispro protamine suspension)

Humalog® Vials

Humalog® Cartridges

Humalog® 200 units/mL KwikPen®

Humalog® Mix25® Cartridges

Humalog® Mix50® Cartridges

Humalog® KwikPen® 
 
Humalog® 200 units/mL KwikPen®

Humalog® Junior KwikPen®

Important safety information for HCPs and patients: Humalog® 200 units/mL KwikPen® (September 2015)    
Humatrope® (somatropin for injection)

HumatroPen® 6 mg

HumatroPen® 12 mg

HumatroPen® 24 mg

Hidden Needle Cover User Manual

Humatrope® Handling Instructions - Video

 
Humulin® (insulin, human biosynthetic)
Humulin® N (insulin isophane [rDNA origin]) NPH
Humulin® R (insulin injection [rDNA origin]) Regular
Humulin® 30/70 (30% insulin injection, 70% insulin isophane [rDNA origin])
Humulin® N Cartridges and KwikPen®
  
Humulin® N Vials

Humulin® R Cartridges and KwikPen®
 
Humulin® R Vials

Humulin® 30/70 Cartridges

Humulin® 30/70 Vials
Humulin® N and Humulin® R KwikPen®    
Jardiance®+ (empagliflozin tablets)   Important Safety Information for HCPs and patients: Jardiance® (May 2016)    
Jentadueto®+ (linagliptin/metformin hydrochloride tablets)    
Lartruvo® (olaratumab)    
Prozac® (fluoxetine hydrochloride)   Health Care Professional Letter (May 2004)    
Reopro® (abciximab) Please see Health Canada’s Drug Product Database website for the current ReoPro® product monograph. ReoPro® is owned and distributed by Janssen Inc.      
Strattera® (atomoxetine)   Health Care Professional Letter (Oct 2011)

Health Care Professional Letter (May 2006)

Health Care Professional Letter (Sept 2005)

Health Care Professional Letter (Feb 2005)

Public Communication  (Oct 2011)

Public Communication (May 2006)

Public Communication (Sept 2005)

Public Communication  (Feb 2005)
   
Synjardy™+ (empagliflozin and metformin hydrochloride tablets)    
Taltz® (ixekizumab)

Taltz® Single-Use Prefilled Autoinjector

Taltz® Single-Use Prefilled Syringe

   
Trajenta®+ (linagliptin)    
Trulicity® (dulaglutide)

Trulicity® Single-Use Pen, 0.75 mg/0.5 mL

Trulicity® Single-Use Pen, 1.5 mg/0.5 mL

   
Zyprexa® (olanzapine)
Zyprexa® Zydis®± (olanzapine)
Zyprexa® IntraMuscular (olanzapine tartrate for injection)
  Health Care Professional Letter (Mar 2004)

Public Communication (Mar 2004)
   



 

User Manuals for Re-useable Devices to be used with Humalog® and Humulin® family of products
HumaPen Luxura®
HumaPen Luxura® HD

HumaPen Memoir®≠
HumaPen Memoir® Quick Guide

No longer offered for sale.

HumaPen Savvio®

 

®  Registered trademark owned by Eli Lilly and Company; used under license.

™ Trademark owned by Eli Lilly and Company; used under license.

®∗ Trademark of ImClone LLC used under license.

™+ and ®+ are trademarks used under license from Boehringer Ingelheim (Canada) Ltd. and such medicines are co-promoted with Eli Lilly Canada Inc.

®± Trademark owned by R.P. Scherer Technologies, Inc., a Catalent Pharma Solutions Company. 



Lilly Canada is committed to diverting expired and/or unused health products from landfills and sewers, and ensuring their safe and effective collection and disposal. We are a member of the Health Products Stewardship Association.


Link to Health Products Stewardship Association web site

Don’t throw them out, visit www.healthsteward.ca.

 

Link to Contact Us page
CONTACT US
Contact Us